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RAS proteins are important direct activators of
p110a, p110g, and p110d type I phosphoinositide
3-kinases (PI3Ks), interacting via an amino-terminal
RAS-binding domain (RBD). Here, we investigate
the regulation of the ubiquitous p110b isoform of
PI3K, implicated in G-protein-coupled receptor
(GPCR) signaling, PTEN-loss-driven cancers, and
thrombocyte function. Unexpectedly, RAS is unable
to interact with p110b, but instead RAC1 and
CDC42 from the RHO subfamily of small GTPases
bind and activate p110b via its RBD. In fibroblasts,
GPCRs couple to PI3K through Dock180/Elmo1-
mediated RAC activation and subsequent interaction
with p110b. Cells frommice carryingmutations in the
p110b RBD show reduced PI3K activity and defec-
tive chemotaxis, and these mice are resistant to
experimental lung fibrosis. These findings revise
our understanding of the regulation of type I PI3K
by showing that both RAS and RHO family GTPases
directly regulate distinct ubiquitous PI3K isoforms
and that RAC activates p110b downstream of
GPCRs.
INTRODUCTION
The type I phosphoinositide 3-kinases (PI3Ks) are critical
signaling proteins involved in the regulation of cell growth, sur-
vival, motility, and metabolism. In mammals, there exist four iso-
forms of the type I PI3K catalytic p110 subunits: a, b, g, and d. Of
these, a and b are ubiquitously expressed, whereas g and d have
more limited distribution, most notably in hematopoietic cells
(Vanhaesebroeck et al., 2010). The lipid kinase activity of
p110a is regulated downstream of receptor tyrosine kinases by
the binding of tyrosine-phosphorylated proteins to its regulatory1050 Cell 153, 1050–1063, May 23, 2013 ª2013 Elsevier Inc. Open accep85 subunit, resulting in attenuation of its autoinhibitory activity.
In addition, activated RAS proteins bind directly to an N-terminal
RAS-binding domain (RBD) on p110a, acting synergistically with
the input from tyrosine-phosphorylated proteins to optimally
activate lipid kinase activity (Rodriguez-Viciana et al., 1994,
1996). Proof of the pathophysiological importance of the direct
interaction of RAS with p110a came from the generation of
mice bearing germline mutations in the RBD of p110a, which
were found to be highly resistant to mutant-RAS-induced lung
and skin cancer formation (Gupta et al., 2007).
The direct binding of RAS to p110g has also been studied in
detail. The 3D structure of RAS bound to p110g has been deter-
mined, and RAS has been shown to activate the lipid kinase ac-
tivity of p110g cooperatively with input fromGbg subunits via the
regulatory p101 subunit (Pacold et al., 2000). Mice with muta-
tions in the RBD of p110g show neutrophil defects in the regula-
tion of PI3K activity by some G-protein-coupled receptors
(GPCRs) (Suire et al., 2006). RAS also has been reported to
bind and activate p110d in vitro (Vanhaesebroeck et al., 1997).
In addition, RBD mutations have been used to demonstrate
that input of RAS binding to the single Drosophila type I PI3K is
critical in insulin-pathway-controlled developmental growth
(Orme et al., 2006) and that RAS binding is required for PI3K acti-
vation by chemoattractants in Dictyostelium (Funamoto et al.,
2002).
p110b has been much less thoroughly studied than p110a. It
appears to be relatively insensitive to activation by growth factor
receptor tyrosine kinase signaling but important downstream of
certain GPCRs, including those for lysophosphatidic acid (LPA)
and sphingosine 1-phosphate (S1P), making p110b the only
GPCR-regulated type I PI3K isoform outside the hematopoietic
system (Ciraolo et al., 2008; Guillermet-Guibert et al., 2008; Jia
et al., 2008). p110b may also play an important role in cancer
because mouse models of breast and prostate cancer, as well
as a number of human cancer cell lines, depend on p110b,
particularly in the setting of PTEN loss (Ciraolo et al., 2008; Jia
et al., 2008). In platelets, p110b is essential for integrin-depen-
dent adhesion and clot formation (Jackson et al., 2005; Martinss under CC BY-NC-ND license.
et al., 2010), leading to the intense effort to develop isoform-
specific p110b inhibitors, some of which are now in clinical
trials as antiplatelet and anticancer agents (NCT01458067,
NCT00688714).
The molecular basis of how p110b can exert these distinct
functions is poorly understood. p110b is overall structurally
similar to other p110 catalytic subunits and engages the very
same p85 type regulatory subunits as p110a, albeit in a some-
what different way (Zhang et al., 2011). Early reports have found
p110b to associate with Gbg subunits from heterotrimeric G pro-
teins, which can directly stimulate its lipid kinase activity in vitro
(Kurosu et al., 1997;Maier et al., 1999). It has, however, remained
entirely unclear whether the p110b RBD contributes to p110b
activation and function, and despite the apparently similar level
of relatedness between the RBDs across the four isoforms, a
systematic analysis of RAS effector proteins failed to detect
any activation of p110b by RAS in cotransfected cells (Rodri-
guez-Viciana et al., 2004).
In this report, we explore the role of p110b regulation
through its RBD for PI3K signaling and function. We present
extensive in vitro work to show that p110b is the only type I
PI3K isoform not regulated by RAS and to identify the RHO
family GTPases RAC and CDC42 as direct isoform-specific
RBD interactors and activators of p110b. We go on to show
that GPCRs couple to PI3K via Dock180/Elmo1-mediated
RAC activation and subsequent interaction with p110b. Mouse
embryonic fibroblasts (MEFs) from p110b RBD mutant mice
show reduced PI3K activity and mice are resistant to bleomy-
cin-induced lung fibrosis, a pathology that has been linked
with LPA signaling. These findings explain longstanding incon-
sistencies and revise our understanding of type I PI3K regula-
tion by small GTP-binding proteins, providing molecular insight
into the regulation and function of the ubiquitous p110b
isoform.
RESULTS
PI3K p110b Is Not a RAS Target Protein
To investigate the role of RAS in regulating p110b, we set out to
characterize the biochemical interaction between the two
in vitro. In glutathione S-transferase (GST) pull-down studies us-
ing recombinant, GTPgS-loaded HRAS, KRAS, and NRAS as
baits, we found strong and specific interaction between all three
RAS proteins and p110a (Figure 1A). In contrast, p110b bound to
none of the RAS proteins, but did bind to RAB5, a previously
identified GTPase interactor of p110b (Christoforidis et al.,
1999). Mutating key residues within the RBD of p110a (T208D/
K227A) abrogated RAS binding, whereas introduction of analo-
gous mutations (see below for details) into p110b did not affect
RAB5 binding. Similar results were obtained when we used re-
combinant full-length GST-p110/p85 complexes to pull down
active RAS or RAB5 proteins (Figure 1B). Moreover, whenwe ex-
pressed constitutively active RAS or RAB5, along with p110a/
p85 or p110b/p85 in COS7 cells, and measured PIP3-levels (Fig-
ure 1C) or steady-state phospho-AKT (Figure S1A available on-
line) as indicators of PI3K activity, HRAS and KRAS strongly
enhanced p110a activity, whereas p110b was not stimulated
by either RAS proteins or RAB5.Cell 153, 1050–1063, May 23, 2An Intact RBD Is Essential for p110b Activity in Cells
Themodest RBD sequence similarity among the four paralogs of
type I PI3K is shown in Figure 1D. Even though the overall struc-
tural organization of the p110b RBD is conserved (Zhang et al.,
2011), we speculated that because we cannot detect any inter-
action with RAS, it might have lost or altered its function. We
therefore mutated two highly conserved key residues within
the p110b RBD to generate a p110b-S205D/K224A double
mutant (p110b-RBD-DM; Figure 1E). Analogous mutations in
p110a and p110g disrupt RAS binding (Gupta et al., 2007; Pa-
cold et al., 2000). In vitro, the basal lipid kinase activity of purified
recombinant p110b-RBD-DMprotein was indistinguishable from
its wild-type counterpart prepared in parallel (Figure 1F). More-
over, p110b-RBD-DM was still stimulated by the addition of pu-
rified recombinant Gbg subunits, alone or in combination with a
platelet-derived growth factor receptor (PDGFR)-derived phos-
photyrosine peptide (pY740), indicating that the RBD mutations
had no intrinsic effect on p110b lipid kinase activity or RBD-inde-
pendent stimulatory input (Figure 1G). However, RBD mutant
p110b was much less active than wild-type when expressed in
COS7 cells (Figures 1H and S1B) even when Gbg subunits
were coexpressed or amyristoylation signal was added, pointing
to a critical role of the RBD for p110b activity in living cells.
p110b Interacts with Distinct RAS Subfamily GTPases
To identify RBD interactors of p110b, we probed all 34 murine
members of the RAS subfamily of small GTPases (RFGs) for
binding to p110b/p85 (Figure S1C). Parallel experiments were
performed with p110a/p85, p110g/p101, and p110d/p85,
respectively (Figure S1D). Strikingly, whereas all non-b isoforms
interacted with the three prototypical RAS proteins and a
partially overlapping subset of closely related RFGs (RRAS1,
RRAS2, MRAS, and ERAS), p110b bound to none of those (Fig-
ure 2A). Instead, p110b exclusively bound to the more distantly
related DIRAS1 and DIRAS2 proteins in a GTP-dependent
manner (Figure S1C). DIRAS selectively bound wild-type and
not RBD mutant p110b (Figure S2B), suggesting binding to the
RBD. However, DIRAS failed to stimulate p110b lipid kinase ac-
tivity in vitro (Figure 2C) and in cells, where constitutively active
DIRAS proteins seemed to repress rather than elevate phos-
pho-AKT when coexpressed along with p110b (Figure 2B), mak-
ing DIRAS an unlikely in vivo activator of p110b.
p110b Is a Direct RAC/CDC42 Target Protein
When comparing DIRAS with RAS, an obvious difference is the
substitution of Asp33 within the G2 box of RAS with Ile37 in
DIRAS (Figure 2D). This substitution is relevant to PI3K binding
because an HRAS-D33I mutant showed attenuated binding to
p110a and DIRAS1-I37D showed reduced binding to p110b,
even though exchange of this residue did not enable RAS bind-
ing to p110b or DIRAS binding to p110a (Figure S2A), pointing to
additional, G2-box-independent determinants of PI3K isoform
specificity. Several members of the RHO subfamily of small
GTPases harbor a hydrophobic isoleucine or valine residue in
this position (Figure S2C), which prompted us to test p110b for
binding to representative RHO family GTPases (Figure S2D).
Surprisingly, p110b bound to both RAC1 and CDC42 in a GTP-
dependent manner. Weaker binding to RHOG and minimal013 ª2013 Elsevier Inc. 1051Open access under CC BY-NC-ND license.
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binding to RHOA was also observed (Figure 2E). Importantly,
RAC1, CDC42, RHOG, and RHOA preparations bound similar
amounts of GTP, indicating proper folding and functionality (Fig-
ure 2E, right lower graph), and a RAC1-I33D mutant showed
reduced binding to p110b (Figure S2E), confirming a key role
of this residue in GTPase binding to p110b.
The RAC1/CDC42-p110b interaction was isoform specific
because neither RAC1 nor CDC42 significantly bound non-b iso-
forms under parallel conditions (Figures 2F and S2F). Strikingly,
GTPgS-loaded RAC1 or CDC42 strongly stimulated p110b lipid
kinase activity in vitro (Figure 2G), alone and in cooperation with
a phosphotyrosine peptide (pY740), or when p110b was com-
plexed with a less inhibitory, truncated p85 (Dp85 schematic in
Figure 3C). Stimulation of p110b by active RAC1 and CDC42
was dose dependent (Figure 2H). Coexpression of constitutively
active RAC1 or CDC42 (Figure S2G, lanes 4–6), but not RHOA
(Figure S2H), along with p110b/p85 in COS7 cells strongly
elevated cellular phospho-AKT and PIP3 levels (Figure 2I), indi-
cating that both GTPases activate p110b in transfected cells.
PIP3 levels were further enhanced by coexpression of Gb1/Gg2
subunits or by myristoylation of p110b (Figure 2I). In contrast,
GTPgS-loaded RAC1/CDC42 did not stimulate p110a in vitro
(Figure S2I), nor did V12-RAC1/CDC42 cooperate with p110a,
p110g, or p110d to elevate cellular phospho-AKT levels (Fig-
ure S2J). Taken together, these data show that the RHO family
GTPases RAC1 and CDC42 bind to p110b in an isoform-specific
manner andpotently anddirectly stimulate its lipid kinaseactivity.
RAC and CDC42 Are RBD Interactors of p110b
We next aimed to confirm that RAC and CDC42 are RBD interac-
tors of p110b. Purified recombinant wild-type p110b/p85 bound
to RAC1 and CDC42 in a concentration-dependent manner,
whereas p110b-RBD-DM/p85 complexes showed no binding
(Figure 3A). Similarly, RBD mutant p110b was not stimulated
by active RAC1 or CDC42 in vitro (Figure 3B) or in cells (Fig-
ure S2E, lanes 7–9). To test whether the BCR homology domain
(BHD) on p85, which had previously been shown to bind RAC
and CDC42 (Bokoch et al., 1996; Zheng et al., 1994), is required
for RAC/CDC42 binding to p110b, we truncated p85 (Dp85 sche-
matic in Figure 3C) and probed for binding of p110b/Dp85 toFigure 1. PI 3-Kinase p110b Is Unable to Interact with RAS
(A) p110b does not bind to GTP-loaded RAS proteins. Purified recombinant, GTP
COS7 cells expressing FLAG-p110a/p85 or FLAG-p110b/p85, wild-type (WT), o
(B) Active RAS proteins do not bind to immobilized p110b/p85. Purified recomb
COS7 cells expressing Myc-tagged, constitutively active HRAS, KRAS, NRAS, a
(C) Active RAS proteins do not stimulate p110b in cells. Lipids were extracted and
of HRAS, KRAS, NRAS, and RAB5, alone or in combination with p110a/p85 or p
(D) Type I PI3K RBDs show moderate sequence similarity. Alignment of amino ac
PIK3CA = p110a, PIK3CG = p110g). Orange represents RAS-binding residues in
(E) Mutation of RBD key residues in p110b. The two point mutations are show
interaction.
(F) Unaltered lipid kinase activity of recombinant p110b-RBD-DM protein. Lipid
complexes (n = 3; mean with SEM).
(G) p110b-RBD-DM protein remains sensitive to Gbg and phosphotyrosine. A r
PDGFR-derived phosphotyrosine peptide (pY740) on the activity of purified reco
(H) Activity of p110b-RBD-DM in living cells is reduced. Lipids were extracted an
p110b/p85. Gbg, coexpression of Gb2 and Gg1; Myr, myristoylated p110b (n = 3
See also Figure S1.
Cell 153, 1050–1063, May 23RAC1 and CDC42 in vitro. Intriguingly, binding was unaffected
by removal of the BHD but completely disrupted when full-length
p85was in complex with RBDmutant p110b, strongly arguing for
the RBD as the RAC/CDC42-binding site. To further corroborate
these findings, we generated 43 single point mutations covering
37 residues across the p110b RBD and assayed these mutants
for binding to RAC1 and CDC42 (Figures 3D, S3A, and S3B).
Of those, 17 mutations of 14 RBD residues affected binding to
both GTPases without affecting p110b protein stability. Several
of these residues were part of the RBDb1 and b2 sheets or the
loop adjacent to the RBDa1 helix (Zhang et al., 2011), areas
known to be important for RAS binding in non-b isoforms (Pacold
et al., 2000). Finally, we employed isothermal titration calorimetry
(ITC) to study thermodynamics of the RAC1/CDC42-p110b inter-
action. In solution, RAC1,GTPgS bound to p110b/Dp85 with a
molar ratio close to 1 and an average Kd of 1.42 mM, whereas
the affinity measured for CDC42,GTPgS was 3.1 mM (Figures
3E and 3F). Similar affinities have been reported for the RAS-
p110a and RAS-p110g interactions (Pacold et al., 2000; Rodri-
guez-Viciana et al., 1996), indicating that RAC1 and CDC42
are plausible RBD interactors of p110b. No binding was
observed between GTPgS-loaded RAC1/CDC42 and p110a or
p110b-RBD-DM, respectively (Figure S3C).
p110b-RBD-DM Mice Show Signs of Reduced PI3K
Activity
To study the role of interactor binding to the p110b RBD for PI3K
signaling in vivo, we generated mice harboring the two p110b
RBD point mutations (S205D/K224A) within their germline.
Homologous recombination in embryonic stem (ES) cells was
employed to replace exon 6 of the murine Pik3cb gene (Fig-
ure S4A), and germline transmission was achieved by eight-
cell embryo injection (Figures S4B and S4C). p110b-RBD-DM
mice were viable and fertile, although numbers of homozygous
animals at the time of biopsy (around day 14) were moderately
reduced (73 where 105 were expected; p < 0.02; Figure 4A), indi-
cating incomplete lethality for undetermined reasons. Newborn
homozygous p110b-RBD-DM pups were smaller than their
wild-type littermates (Figure 4B). The size difference in adult
mice was subtle but remained significant when same-sexgS-loaded HRAS, KRAS, NRAS, and RAB5 were incubated with lysates from
r RBD double mutant (DM).
inant GST-p110a/p85 and GST-p110b/p85 were incubated with lysates from
nd RAB5.
PIP3 levels measured fromCOS7 cells expressing constitutively active mutants
110b/p85 (n = 3; mean with SD; one-way ANOVA).
id sequences of all four type I PI3K RBDs (PIK3CB = p110b, PIK3CD = p110d,
p110g, and arrows represent conserved ‘‘RAS-binding’’ residues.
n together with hypothetical interactor residues modeled on the RAS-p110g
kinase assay assessing basal activities of purified recombinant p110b/p85
epresentative lipid kinase assay assessing effect of recombinant Gbg and a
mbinant p85/p110b-WT and p85/p110b-RBD-DM is shown.
d PIP3 levels measured from COS7 cells expressing wild-type or RBD mutant
; mean with SEM; paired t test).
1053, 2013 ª2013 Elsevier Inc. Open access under CC BY-NC-ND license.
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Figure 2. RAC and CDC42 Directly Bind and
Active p110b
(A) p110b interacts with distinct RAS subfamily
GTPases to non-b isoforms. Table summarizes
results from GST pull-down assays (Figures S1C
and S1D) probing 34 murine RAS subfamily
GTPases for GTP-dependent binding of type I
PI3K isoforms (, no binding; +, specific bind-
ing; ++, strong binding; +++, very strong binding).
(B) DIRAS1/-2 do not stimulate p110b in cells.
Constitutively active DIRAS1 or DIRAS2 were
coexpressed with FLAG-p110b/p85 in COS7 cells.
(C) DIRAS does not stimulate p110b lipid kinase
activity in vitro. Shown is a lipid kinase assay
assessing the effect of purified recombinant,
GTPgS-loaded DIRAS1 on p85/p110b (WT) and
p85/p110b-RBD-DM (DM) activity (n = 3; mean
with SEM).
(D) G2 box sequences of H-/KRAS, DIRAS1/-2 and
RAC1/CDC42. Color-coded amino acid sequence
alignment of the N termini of indicated small
GTPases. A square frame highlights the G2 box
sequence, and the variant residue (D33 in RAS) is
shown in gray.
(E) RHO GTPases directly bind p110b in a GTP-
dependent manner. Purified recombinant, GDP/
GTPgS-loaded RHO GTPases were incubated
with purified recombinant p110b/p85 (50 nM).
Top: representative experiment; left: quan-
tification (n = 2; mean with SEM); right: 3[H]-GTP
uptake of GTPase preparations (n = 2; mean with
SEM).
(F) Binding of p110b to RAC1 and CDC42 is
isoform specific. Purified recombinant GDP/
GTPgS-loaded RAC1 and CDC42 were incubated
with lysates from COS7 cells expressing FLAG-
tagged p110a/p85, p110b/p85, p110g/p101, and
p110d/p85.
(G) RAC1 and CDC42 directly stimulate p110b
lipid kinase activity. Purified recombinant GTPgS-
loaded RAC1/CDC42 (1 mM) were added to
purified recombinant p110b/p85, and lipid kinase
activity was assessed in vitro. pTyr, phos-
photyrosine peptide (pY740, 10 mM); Dp85,
truncated p85, schematic in Figure 3C (n = 2;
mean with SD).
(H) RAC1 and CDC42 dose-dependently stimulate
p110b lipid kinase activity. Increasing concentra-
tions of purified recombinant GTPgS-loaded
RAC1/CDC42 were added to purified recombinant
p110b/Dp85, and lipid kinase activity was as-
sessed in vitro (n = 3; mean with SEM).
(I) RAC1 and CDC42 activate p110b in cells.
Lipids were extracted and PIP3 levels measured
from COS7 cells expressing constitutively active RAC1 or CDC42, alone or in combination with FLAG-p110b/p85. Gbg, coexpression of Gb2 and Gg1; Myr,
myristoylated p110b (n = 2; mean with SD). Western blots show expression levels of FLAG-p110b and Myc-tagged GTPases.
See also Figure S2.litter- and cage-mates were compared (Figure 4C). MEFs
homozygous for the p110b RBDmutation proliferated at a signif-
icantly slower rate than their wild-type counterparts (Figure 4D),
whichwas reflectedbya higher percentage of cells inG1 (1% fetal
calf serum [FCS]: 56.7% ± 0.32% versus 64.2% ± 0.53%, n = 4,
p < 0.001; 10% FCS: 47.5% ± 3.0% versus 52.2% ± 3.9%,
n = 4, p < 0.05), fewer cells in G2 (1% FCS: 24.5% ± 1.4% versus1054 Cell 153, 1050–1063, May 23, 2013 ª2013 Elsevier Inc. Open acce21.0% ± 1.9%, n = 4, p < 0.05; 10% FCS: 23.9% ± 1.4% versus
21.1% ± 1.6%, n = 4, p < 0.05) and fewer cells in S phase for 1%
FCS (1% FCS: 13.3% ± 1.0% versus 11.0% ± 169%, n = 4, p <
0.05) (Figure 4E). Moreover, p110b-RBD-DM MEFs showed
lower steady-state phospho-AKT levels (Figure 4F), suggesting
that stimulatory signaling to p110b via its RBD contributes to
PI3K activity in vivo. Expression levels of p110b, p110a, andss under CC BY-NC-ND license.
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Figure 3. RACandCDC42Are Interactors of
the p110b RAS-Binding Domain
(A) RAC1 and CDC42 do not bind p110b-RBD-DM
in vitro. Purified recombinant p85/p110b (WT) and
p85/p110b-RBD-DM (DM) protein complexes, at
the indicated concentrations, were incubated with
GST-tagged, GDP/GTPgS-loaded RAC1 and
CDC42.
(B) RAC1 and CDC42 do not stimulate
p110b-RBD-DM lipid kinase activity. Purified re-
combinant GTPgS-loaded RAC1/CDC42 (1 mM)
were added to purified recombinant p85/
p110b-WT or p85/p110b-RBD-DM in lipid kinase
assays (n = 2; mean with SD). Data are part of
experiment shown in Figure 2G.
(C) The N terminus of p85 is not required for p110b
binding to RAC1/CDC42. Purified recombinant
p110b/p85 protein complexes were incubated
with GST-tagged, GDP/GTPgS-loaded RAC1,
CDC42 and RAB5. Lanes 1/2: p85/p110b-WT;
lanes 3/4: Dp85/p110b-WT; lanes 5/6: p85/
p110b-RBD-DM. Dp85 is detailed in the sche-
matic.
(D) Single RBD point mutations disrupt p110b
binding to RAC1/CDC42. Amino acid alignment of
type I PI3K RBDs with secondary structure ele-
ments of p110b (H, helix; E, b sheet) and color
coding to illustrate effect of residue mutation on
p110b binding to RAC1/CDC42. Green, unaltered
binding; red, reduced/abolished binding; blue,
unstable protein; yellow, p110b-RBD-DM resi-
dues; black, notmutated (Figures S3A and S3B for
pull-down assays and table).
(E) Thermodynamic characterization of the RAC1/
CDC42-p110b interaction by ITC. Binding of pu-
rified recombinant GTPgS-loaded RAC1 and
CDC42 to purified recombinant p110b/D85 in so-
lution was studied. Top: differential power over
time; bottom: thermal energy (H) over molar ratio.
(F) Table summarizes results from ITC experi-
ments. Numbers represent Kd values determined
in independent experiments. n.b., no binding.
See also Figure S3.p85 were indistinguishable among the genotypes (Figure S4D),
and the stoichiometry of p110 subunit binding to p85 was undis-
turbed (Figure S4E).
RAC and CDC42 Regulate p110b In Vivo
To determine whether RAC and CDC42 are upstream activators
of p110b in vivo, we transfected wild-type and p110b-RBD-DM
MEFs with small interfering RNA (siRNA) pools (Dharmacon On-
target plus) targeting theseGTPases (Figure 4G). Although single
knockdowns had only minor effects, combined knockdown ofCell 153, 1050–1063, May 23, 2013 ª2013 Elsevier IRAC1 and CDC42 significantly lowered
phospho-AKT levels in wild-type, but not
in p110b-RBD-DM cells, closing the gap
in steady-state phospho-AKT levels be-
tween the genotypes and suggesting
that endogenous RAC1 and CDC42
cooperatively activate p110b via its
RBD. We next acutely expressed consti-tutively active mutants of RAC1 and CDC42 in wild-type,
p110a-, and p110b-knockout MEFs (Figures 4H and S4F). Both
RAC1 and CDC42 increased steady-state phospho-AKT levels
in wild-type and p110a-deleted cells but not in p110b-knockout
MEFs. Moreover, expression of V12-RAC1 and V12-CDC42
failed to elevate phospho-AKT levels in p110b-RBD-DM MEFs,
whereas V12-HRAS did so in both wild-type and p110b-RBD-
DM MEFs (Figure 4I). Taken together, these findings indicate
that RAC1 and CDC42 activate PI3K in living cells by isoform-
specific regulation of p110b through its RBD.1055nc. Open access under CC BY-NC-ND license.
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Figure 4. RAC/CDC42 Binding to p110b
Regulates PI3K Activity In Vivo
(A) Reduced numbers of homozygous
p110b-RBD-DM mice. Offspring from HET 3 HET
crosses was genotyped at 2 weeks of age (n = 389;
p < 0.02, chi-square analysis).
(B) Newborn p110b-RBD-DM pups are smaller.
Newborn pups from HET 3 HET crosses were
collected on the morning of birth, weighed, and
genotyped (n = 31; mean ±SEM; p = 0.011, t test).
(C) Adult p110b-RBD-DM mice are smaller than
their wild-type littermates. Weights of adult ho-
mozygous p110b-RBD-DM mice (12–30 weeks
old) were compared to same-cage wild-type lit-
termates (n = 39; mean ±SEM; paired t test).
(D) Reduced proliferation of p110b-RBD-DM
MEFs. Early passage primary MEFs were grown in
culture following amodified 3T3 protocol (n = 2 per
genotype). Population doubling rate was calcu-
lated as PDR = logðnðday 3Þ=nðseededÞÞ=log 2
(mean ±SEM; p < 0.001, two-way ANOVA).
(E) Accumulation of p110b-RBD-DM cells in G1.
Cell-cycle profiles of early passage wild-type and
homozygous p110b-RBD-DM primary MEFs
growing in 1% or 10% FCS (n = 4, means; SEM in
the Results section).
(F) p110b-RBD-DM MEFs show reduced steady-
state phospho-AKT levels. Wild-type and
p110b-RBD-DM MEFs were maintained in cell
culture medium supplemented with 0%, 1%, or
10% FCS and harvested for western blot analysis.
(G) RAC1 and CDC42 cooperatively sustain
phospho-AKT levels in wild-type MEFs. Wild-type
and p110b-RBD-DM MEFs were transfected with
scrambled duplex or gene-specific siRNA pools
targeting RAC1, CDC42, or both and harvested for
western blot analysis 30 hr after transfection.
Graph shows phospho-AKT normalized to total
AKT (n = 3; mean with SEM, one-way ANOVA).
(H) RAC1 and CDC42 activate p110b in vivo.
Myc-V12-RAC1 and Myc-V12-CDC42 were
nucleofected into immortalized wild-type,
p110a-knockout, and p110b-knockout MEFs,
along with a kinase-dead AKT reporter construct.
The next day, cells were serum starved and har-
vested for western blot.
(I) RAC and CDC42 fail to activate PI3K in
p110b-RBD-DM cells. Myc-V12-RAC1, Myc-V12-
CDC42, orMyc-V12-HRASwere nucleofected into
wild-type and p110b-RBD-DMMEFs as described
in (H).
See also Figure S4.Activation of p110b Downstream of GPCRs Requires an
Intact RBD
To study whether the p110b RBD is required for coupling p110b
to GPCRs, we stimulated wild-type and p110b-RBD-DM MEFs
with the lipid growth factors and GPCR agonists LPA and S1P.1056 Cell 153, 1050–1063, May 23, 2013 ª2013 Elsevier Inc. Open access under CC BY-NC-ND license.LPA and S1P dose-dependently induced
both AKT and ERK phosphorylation in
wild-type cells (Figures 5A and S5A).
These responses were sensitive to
pertussis toxin (Figure S5B), confirmingGPCR involvement. In p110b-RBD-DM MEFs, LPA- and S1P-
induced phosphorylation of AKT was strongly diminished,
whereas ERK phosphorylation was undisturbed (Figures 5A
and S5A). Also, in time course experiments, AKT phosphoryla-
tion was more transient when the p110b RBD was mutated
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Figure 5. RACActivates p110bDownstream
of GPCRs
(A) LPA-induced AKT phosphorylation is attenu-
ated in p110b-RBD-DM MEFs. Primary wild-type
and homozygous p110b-RBD-DM MEFs were
serum starved and stimulated with LPA for 5 min.
(B) LPA-induced AKT phosphorylation is more
transient in p110b-RBD-DM MEFs. Primary wild-
type and p110b-RBD-DM MEFs were serum
starved and stimulated with LPA (10 mM) for indi-
cated time periods.
(C) LPA-induced AKT phosphorylation is entirely
dependent on p110b. Immortalized wild-
type, p110a-knockout, p110b-knockout, and
p110b-RBD-DM MEFs were serum starved and
stimulated with indicated doses of LPA for 5 min.
(D) LPA-/S1P-induced AKT phosphorylation re-
quires RAC. Immortalized wild-type MEFs were
transfected with scrambled duplex or gene-spe-
cific siRNA pools targeting RAC1, CDC42 or both.
Serum-starved cells were stimulated with LPA
(10 mM) or S1P (1 mM) for 5 min.
(E) LPA-/S1P-induced AKT phosphorylation re-
quires RAC activity.
Immortalized wild-type MEFs were serum starved,
preincubated with EHT1864 for 30 min, and stim-
ulated with LPA (10 mM) or S1P (1 mM) for 5 min.
(F) LPA induces rapid and transient activation of
RAC. Serum-starved wild-type and p110b-RBD-
DM MEFs were stimulated with LPA (10 mM) for
indicated periods of time. RAC,GTP and total RAC
were measured as described in the Extended
Experimental Procedures (n = 3; mean with SEM).
See also Figure S5.(Figure 5B and not shown). In contrast, p110b-RBD-DM MEFs
responded normally to epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), and insulin in dose-response (Fig-
ure S5C) and time course experiments (data not shown).
Notably, in p110b-knockout cells, AKT phosphorylation in
response to LPA was completely abolished (Figure 5C), indi-
cating that the RBD is essential for much but not all p110b acti-
vation downstream of GPCRs.
Activation of p110b Downstream of GPCRs Requires
RAC
To test whether the identified p110b RBD interactors are
required for linking p110b to GPCRs, we knocked down RAC1
and CDC42 in wild-type MEFs. Knockdown of RAC1 strongly
impacted LPA/S1P-induced AKT phosphorylation, knockdown
of CDC42 had only minor effects, and combination knockdownCell 153, 1050–1063, May 23, 2013 ª2013 Elsevier Iof both RAC1 and CDC42 had little addi-
tional effect compared to RAC1 knock-
down alone (Figure 5D). Deconvolution
experiments using single siRNA oligonu-
cleotides confirmed the leading role of
RAC1 in this pathway (Figure S5D).
Neither RAC1 nor CDC42 knockdown
affected LPA/S1P-induced phosphoryla-
tion of ERK or activation of either pathwayinduced by tyrosine kinase receptor agonists (EGF, PDGF, and
insulin; Figure S5E). Similarly, EHT1864, a direct inhibitor of
RAC but not CDC42 activation, dose-dependently inhibited
AKT phosphorylation induced by LPA/S1P (Figure 5E), but not
EGF, PDGF, or insulin (Figure S5F). Therefore, acute loss or inhi-
bition of RAC phenocopied the signaling defect observed in
p110b-RBD-DM MEFs. In line with this, RAC was activated
very rapidly upon LPA stimulation, reaching its peak activity
within 20 s (Figure 5F).
Dock180/Elmo1 Activates RAC Downstream of GPCRs
and Upstream of p110b
To provide further mechanistic insight into the GPCR-RAC-
p110b pathway, we performed a small candidate siRNA screen
to identify the guanine nucleotide exchange factor (RAC-GEF)
involved. Transfection of wild-type MEFs with siRNA pools1057nc. Open access under CC BY-NC-ND license.
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Figure 6. Dock180/Elmo1 Activate RAC
Downstream of GPCRs and Upstream of
p110b
(A) siRNA pools targeting Dbl family RAC-GEFs fail
to affect LPA-induced AKT phosphorylation.
Immortalized wild-type MEFs were transfected
with scrambled duplex or gene-specific siRNA
pools targeting indicated Dbl family RAC-GEFs. A
total of 48 hr after transfection, serum-starved
cells were stimulated with LPA (10 mM) for 5 min.
(B) Dock180 and Elmo1 are essential for LPA-
induced AKT phosphorylation. Immortalized wild-
type MEFs were transfected with scrambled
duplex or gene-specific siRNA pools targeting
indicated Dock family RAC-GEFs. Then 48 hr after
transfection, serum-starved cells were stimulated
with LPA (10 mM) for 5 min.
(C) Dock180 is essential for LPA-induced RAC
activation. Immortalized wild-type MEFs, trans-
fected with scrambled duplex or Dock180-specific
siRNA pools, were stimulated with LPA (10 mM) or
EGF (10 ng/ml) for 20 s and active RAC was
quantified (n = 4; mean with SEM; t test; bottom: a
representative experiment).
(D) LPA-induced RAC activation is PI3K indepen-
dent. Immortalized MEFs were preincubated with
PTX (200 ng/ml, 16 hr) or GDC0941 (10 mM, 1 hr)
and stimulated with LPA (10 mM) for the indicated
time periods (n = 4; mean with SEM; one-way
ANOVA; bottom: representative lysates).
(E) Gbg subunits directly bind to the N terminus of
Elmo1. GST-tagged full-length Elmo1 and frag-
ments as shown (schematic) were incubated with
lysates from COS7 cells expressing Gb2 and Gg1.
Bound Gb was detected by western blot.
(F) Model of GPCR-induced p110b activation. See
text for details.
See also Figure S6.targeting the Dbl family RAC-GEFs Vav1-3, PREX1/2, and a-/
b-PIX had no clear effect on LPA/S1P-induced AKT phosphory-
lation (Figures 6A and S6A). In contrast, knockdown of the Dock
family RAC-GEF Dock180 or its adaptor protein Elmo1 interfered
with AKT phosphorylation induced by LPA and S1P (Figure 6B
and S6B), but not by EGF, PDGF, and insulin (Figure S6C). Spec-
ificity of results was confirmed in deconvolution experiments us-
ing individual siRNA oligonucleotides targeting Dock180 and
Elmo1 (Figures S6D and S6E). Knockdown of Elmo2 had no ef-
fect (Figure S6F). Moreover, knockdown of Dock180 abolished
LPA- but not EGF-induced RAC activation (Figure 6C), firmly1058 Cell 153, 1050–1063, May 23, 2013 ª2013 Elsevier Inc. Open access under CC BY-NC-ND license.placing Dock180/Elmo1 downstream of
the LPA receptor and upstream of RAC
and p110b. The DHR-1 domain of
Dock180 has been shown to bind PIP3
(Coˆte´ et al., 2005), raising the possibility
of a PIP3-driven feedback loop, in which
RAC would be upstream and down-
stream of p110b. However, whereas sen-
sitive to pertussis toxin, LPA-induced
RAC activation was entirely insensitive
to PI3K inhibition by GDC0941, a pantype I PI3K inhibitor, placing all detectable RAC activation up-
stream of p110b (Figure 6D). Recently, Dictyostelium ElmoE
has been reported to be a direct Gbg effector (Yan et al.,
2012).We thus probedGbg subunits for direct binding to purified
recombinant Elmo1 (Figure 6E) and found Gbg to strongly bind
to full-length Elmo and several N-terminal fragments. This
altogether suggests a model in which Dock180 is recruited
downstream of GPCRs, possibly through binding of Gbg to the
N terminus of Elmo1. At the same time, p110b is directly re-
cruited by Gbg. RAC is activated in proximity to p110b and binds
to the RBD to fully activate p110b lipid kinase activity (schematic
in Figure 6F). We could not detect any tyrosine phosphorylation
on p85 in response to LPA (Figure S6G), and the tyrosine kinase
inhibitors dasatinib, erlotinib, and PP2 (all at 1 mM) had no effect
on the signaling pathway studied (data not shown).
Disruption of the LPA-Dock180/Elmo1-RAC-p110b Axis
Affects Fibroblast Chemotaxis
To assess the functional importance of the Dock180/Elmo1-
RAC-p110b signaling axis for fibroblast chemotaxis, we em-
ployed transwell filter assays to study migration in gradients of
LPA and PDGF. p110b-RBD-DM MEFs showed significantly
reduced migration in LPA but not PDGF gradients (Figure 7A).
Similarly, wild-type MEFs transfected with siRNA pools targeting
Dock180, Elmo1, or RAC1 showed defective migration in gradi-
ents of LPA but not PDGF (Figure 7B), pointing to the specificity
of this pathway for GPCR-induced chemotaxis. In contrast, PI3K
activity was required for normal migration in either gradient,
because pretreatment of wild-type cells with GDC0941 strongly
affected migration toward LPA and PDGF, whereas pretreat-
ment of cells with pertussis toxin selectively blocked migration
in LPA gradients (Figure S7A).
In agreement with a key role of RAC upstream of p110b in
fibroblast migration, acute expression of constitutively active
RAC (V12-RAC1) stimulated migration of wild-type but not
p110b-RBD-DM MEFs in the absence of chemoattractant and
in the presence of a low concentration of LPA (10 nM) in the lower
chamber, whereas migration toward 1% FCS was largely unaf-
fected (Figure S7B).
p110b-RBD-DM Mice Are Protected from Bleomycin-
Induced Lung Fibrosis
LPA has been identified as important fibroblast chemoattractant
in bleomycin-induced lung fibrosis, a well-studied mouse model
of human fibrotic lung disease, and was found to be elevated in
patients with idiopathic lung fibrosis (Tager et al., 2008). We
therefore wondered whether the disruption of p110b activation
by LPA in p110b-RBD-DM mice would be sufficient to affect
experimental lung fibrosis. Following a single intratracheal appli-
cation of bleomycin, a quarter of all wild-type animals died or had
to be culled according to local animal welfare regulations,
whereas all p110b-RBD-DM mice survived (Figure 7C). Also,
wild-type but not p110b-RBD-DM mice significantly lost body
weight (Figure 7D) upon bleomycin treatment. Lung weights
increased in both groups, but to a significantly lesser extent in
p110b-RBD-DM mice (Figure S7C). Histology of lungs 14 days
after bleomycin challenge revealed extended areas of fibrotic
changes in wild-type animals (Figure 7E, hematoxylin and eosin
staining [H&E], top), characterized by accumulation of activated,
smooth muscle antigen-positive fibroblasts (Figure 7E, middle)
and deposition of crosslinked collagen fibers (Figure 7E, Sirius
red, bottom). Changes in p110b-RBD-DM mice were milder,
with some mice showing almost normal lungs and others
showing more limited areas of fibrosis. Morphometric analysis
of multiple nonoverlapping lung areas confirmed the differences
between the genotypes: transparent lung areas were signifi-
cantly reduced (Figures 7F and S7D) and SMA-positive areas
significantly increased (Figure 7G and S7E) in wild-type but not
p110b-RBD-DM mice when compared to saline controls.Cell 153, 1050–1063, May 23DISCUSSION
RAS Proteins Do Not Regulate the Ubiquitous p110b
Isoform
In this study, we show that, in contrast to what has been widely
presumed, RAS is not a general regulator of type I PI3Ks. We find
that out of the two ubiquitously expressed PI3K isoforms, only
p110a is regulated by RAS, whereas p110b is a direct RAC
and CDC42 target protein, indicating that key members of the
pivotal RAS and RHO families of small G proteins directly regu-
late type I PI3Ks, with each family controlling their own distinct
ubiquitous p110 isoform.
That p110b proved unable to physically and functionally
interact with RAS is unexpected given the presence of a moder-
ately conserved PI3K-type RBD in all four type I PI3K p110 cat-
alytic subunits (Pacold et al., 2000). Comparison between the
published structures of the four RBDs in their interactor-free
states reveals little pointing to the distinct interactor specificity
of p110b (R. Chaleil and P. Bates, personal communication).
p110b is not only unable to interact with RAS under conditions
readily revealing the transient, low-affinity interactions of RAS
with other isoforms, but it also has an entirely distinct RAS super-
family GTPase interactor profile with a subfamily switch from
RAS to RHO at the core of it, making any, for whatever reason,
undetectable interaction with RAS unlikely. RBDs, classified on
grounds of a ubiquitin fold structure with interactor specificities
distinct from RAS, are not uncommon, as exemplified by the hu-
man formin FHOD1, a RAC interactor (Schulte et al., 2008), or the
N terminus of Elmo1, shown to bind RHOG and the ARF family
member ARL4A (Patel et al., 2011).
RAC and CDC42 Are Isoform-Specific RBD Interactors
of p110b
Our biochemical experimentation identifies RAC1 and CDC42 as
RBD interactors of p110b. An association of PI3K with RAC and
CDC42 was first noticed nearly 20 years ago (Tolias et al.,
1995), butwasattributed toRAC/CDC42binding to theamino-ter-
minal BHD on p85, which has sequence homology to RHO-GAP
domains (Bokoch et al., 1996; Zheng et al., 1994). These studies
left the epistasis of information transfer between RAC/CDC42
and PI3K unclear. In retrospect, all functional data from these
studies can be explained by the presence of p110b in the cell ly-
sates and PI3K preparations used. Only the reported binding of
RAC and CDC42 to recombinant p85 remains puzzling. We did
not studymonomeric p85, which has not been found in living cells
(Geering et al., 2007), but our biochemical data strongly argue
against an involvement of p85 in the RAC/CDC42-p110b interac-
tion, because (1) RAC1 and CDC42 do not interact with p110a/
p85 or p110d/p85, (2) RAC1 and CDC42 bind normally to p110b
in theabsenceof thep85BHdomain, and (3)RBDpointmutations
abrogateRAC1andCDC42binding to p110b in complexwith full-
length p85. A body of literature has accumulated identifying RAC
orCDC42 as essential upstreamactivators of PI3K in various sys-
tems (Keely et al., 1997; Srinivasan et al., 2003; Weiner et al.,
2002), but straightforward analysis of the relationship between
RHO family GTPases and PI3K has been difficult, mainly because
RAC andCDC42 also act downstream of PI3K, activated through
PIP3-dependent GEFs (Welch et al., 2003). A very recent study1059, 2013 ª2013 Elsevier Inc. Open access under CC BY-NC-ND license.
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Figure 7. p110b-RBD-DM Mice Are Pro-
tected from Bleomycin-Induced Lung
Fibrosis
(A) p110b-RBD-DM fibroblasts show reduced
migration in gradients of LPA. Migration of wild-
type and p110b-RBD-DM MEFs in gradients of
LPA and PDGF was assessed in transwell filter
assays (n = 3; mean with SD; one-way ANOVA).
(B) Dock180, Elmo1, and RAC1 are required for
fibroblast migration in gradients of LPA. Immor-
talized wild-type MEFs were transfected with
scrambled duplex or gene-specific siRNA pools
targeting Dock180, Elmo1, or RAC1. Migration in
gradients of LPA and PDGF was assessed in
transwell filter assays and cell numbers were
normalized to control conditions (n = 4; mean with
SEM; one-way ANOVA).
(C) p110b-RBD-DM mice are protected against
death from bleomycin-induced lung damage.
Wild-type and homozygous p110b-RBD-DM mice
were treated with a single intratracheal dose of
bleomycin (1.25 U/kg) and observed for 14 days
(n = 16 mice per genotype; Mantel-Cox test).
(D) p110b-RBD-DM mice are protected against
weight loss following bleomycin instillation. Wild-
type and p110b-RBD-DM mice received a single
intratracheal dose of saline (n = 3 per genotype) or
bleomycin (n = 10 per genotype) and weights were
taken 14 days later (mean ±SEM; one-way
ANOVA).
(E) p110b-RBD-DM mice are protected from
bleomycin-induced lung fibrosis. Representative
lung areas from wild-type and homozygous
p110b-RBD-DMmice 14 days after treatment with
intratracheal bleomycin (34 magnification). Top:
H&E; middle: IHC for a-SMA; bottom: Sirius red.
(F) p110b-RBD-DM mice are protected against
loss of transparent lung areas following bleomycin
instillation. Lungs were analyzed by H&E 14 days
after bleomycin challenge. Multiple nonoverlap-
ping areas of representative sections from each
lung were photographed and transparent (white)
areas were quantified using Nikon NIS elements
software (mean ±SEM; one-way ANOVA; see
Figure S7C for raw data).
(G) p110b-RBD-DM mice accumulate fewer
activated lung fibroblasts following bleomycin
instillation. Lungs were analyzed by immunohis-
tochemistry for smooth muscle antigen (a-SMA)
14 days after bleomycin challenge. Multiple
nonoverlapping areas of representative sections
from each lung were photographed and SMA-
positive (brown) areas were quantified using Nikon
NIS elements software (mean ±SEM; one-way
ANOVA; see Figure S7D for raw data).
See also Figure S7.
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using microscopy-based assays in transfected cells revisited the
interaction of small GTPases and PI3K, confirming that both
active RAS and RHO family GTPases can activate PI3K in living
cells. However, based on experimentation exclusively with a
p110a reporter construct, the authors interpreted PI3K regulation
by RHO family members as indirect (Yang et al., 2012).
RAC/CDC42 Binding to p110b Controls PI3K Activity
In Vivo
Our findings in MEFs suggest that RAC1 and CDC42 coopera-
tively control steady-state PI3K activity in living cells by iso-
form-specific activation of p110b and that this requires the
p110b RBD. A model in which p110b provides basal, low-level
PI3K activity has been proposed in the context of insulin
signaling (Knight et al., 2006), and data showing PTEN-loss-
driven prostate cancers to be entirely dependent on p110b, as
well as metabolic findings in p110b kinase-dead mice, have
been interpreted in the same way (Ciraolo et al., 2008; Jia
et al., 2008). Our data point to RAC1 and CDC42 as drivers of
such a basal, p110b-controlled activity, an idea consistent with
a previous report finding that ectopic expression of wild-type
but not RBDmutant p110b is sufficient to transform chicken em-
bryo fibroblasts (Kang et al., 2006). It will be interesting to explore
the oncogenic potential of the RAC/CDC42-p110b interaction in
the setting of PTEN loss and also in the context of the recently
discovered activating mutations in RAC (Hodis et al., 2012;
Krauthammer et al., 2012) in human melanomas, where p110b
could be an important downstream target.
GPCRs Activate p110b through its RBD
A firm body of in vivo evidence (Ciraolo et al., 2008; Guillermet-
Guibert et al., 2008; Jia et al., 2008) has established p110b as
a GPCR-regulated PI3K isoform. We find that mutation of the
p110b RBD strongly attenuates p110b activation downstream
of GPCRs, highlighting the importance of the RBD for p110b
key signaling functions. The residual p110b activity in
p110b-RBD-DM MEFs argues for a second, RBD-independent
activation route, for which direct binding of Gbg to p110b (Dbouk
et al., 2012) is themost obvious candidate. A puzzling question is
whether a cooperative effect of RBD interactor and Gbg binding
to p110b can suffice to fully activate p110b, or if additional phos-
photyrosine input is required to overcome the strong inhibition of
lipid kinase activity imposed by p85 (Zhang et al., 2011). Trans-
activation of receptor tyrosine kinases has been suggested to
activate p110b downstream of GPCRs (Yart et al., 2002).
Although we found no effect of tyrosine kinase inhibitors and
no p85 tyrosine phosphorylation in response to LPA in support
of such a mechanism in MEFs, there is evidence for cooperative
GPCR and phosphotyrosine signaling to p110b in leukocytes
(Kulkarni et al., 2011), and such a scenario appears possible in
thrombocytes, where p110b is activated by integrins, ITAM-
bearing receptors, and GPCRs (Martin et al., 2010).
Dock180/Elmo1 Couples GPCRs to RAC and p110b
RAC1 is essential for p110b activation downstream of the
GPCRs for LPA and S1P, and the RAC-GEF Dock180/Elmo1 is
upstream of both RAC and p110b in this pathway. The Dock/
Elmo-RAC signaling axis is a highly conserved pathway control-Cell 153, 1050–1063, Mayling RAC-dependent key functions such as actin remodeling,
migration, and phagocytosis (Coˆte´ et al., 2005). Recent findings
in Dictyostelium have directly linked Gbg subunits from GPCRs
to Dock/Elmo-RAC and the cytoskeleton (Yan et al., 2012).
Reminiscent of Dictyostelium ElmoE, we find the N terminus of
human Elmo1 to directly bind Gbg subunits, suggesting conser-
vation of this pathway in mammals. In line with this, PI3K activity
is not required for RAC activation by LPA, placing p110b entirely
downstream of RAC in fibroblasts, which contrasts with a pro-
posed PIP3-driven feedback loop controlling RAC activity up-
stream and downstream of PI3K in leukocytes (Weiner et al.,
2002). Although PI3K is not required to activate RAC, it is still
essential for fibroblast migration in gradients of LPA, indicating
that PIP3-regulated pathways distinct from RAC activation
contribute to GPCR-driven chemotaxis. Importantly, whereas
our findings identify Dock180/Elmo1 downstream of LPA/S1P
in MEFs, our experiments cannot rule out involvement of other
RAC-GEFs within this pathway. We also cannot directly prove
that the role of Dock180/Elmo1 in controlling fibroblast migration
is exclusively and directly through activation of RAC upstream of
p110b. Finally, different GPCRs and other cell types may signal
through RAC-GEFs other than Dock180/Elmo1, and further
studies will be required to determine whether the Dock180/
Elmo1-RAC1-p110b axis is a fixed signaling module or just one
example of how RAC/CDC42 is activated upstream of p110b.
Overall, the picture that emerges from these studies is one in
which p110b regulation by GPCRs operates through a two-track
signaling pathway with direct and indirect input into p110b. The
direct route involves Gbg interaction with p110b, whereas the
indirect route goes through stimulation of RAC via Dock180/
Elmo1, possibly also recruited through Gbg (see Figure 6F).
Such two-track wiring is reminiscent of receptor tyrosine kinase
regulation of p110a via p85 interaction with tyrosine-phosphory-
lated receptor or adaptor protein and Grb2-Sos-RAS-p110a
interaction. It can be speculated that this signaling logic might
provide an improved ability to amplify a weak signal input or
might increase the possibility for fine-tuning the signal through
crosstalk of other pathways onto components such as
Dock180/Elmo1, RAC itself, or RAC-GAPs terminating RAC ac-
tivity. Another interesting issue is whether such Gbg-Elmo1
and Gbg-p110b interactions are mutually exclusive or can occur
in a heterotrimeric complex. At present, we cannot distinguish
between a model in which one Gbg protein heterodimer binds
directly to both Elmo1 and p110b simultaneously and one in
which Elmo and p110b are engaged by two different Gbg protein
heterodimers (as shown in Figure 6F).
See Supplemental Information online for the Extended Discus-
sion, including information on other GTPase interactors of
p110b, the phenotype of p110b-RBD mutant mice, and resis-
tance of these mice to bleomycin-induced lung fibrosis.
EXPERIMENTAL PROCEDURES
Detailed procedures are described in the Extended Experimental Procedures.
Isothermal Titration Calorimetry
Purified recombinant soluble PI3K protein complexes were loaded into the cell
of a MicroCal iTC200 microcalorimeter at concentrations of approximately
20 mM. Nucleotide-loaded GTPases were loaded into the syringe at 200 mM.106123, 2013 ª2013 Elsevier Inc. Open access under CC BY-NC-ND license.
In a typical experiment, 16 injections of GTPase into the cell were recorded at
15C, and relevant thermodynamic parameters were analyzed and calculated
using the instrument’s software (Origin).
Bleomycin-Induced Lung Fibrosis
All animal experimentation was carried out in compliance with UKHomeOffice
animal welfare regulations. Age- and sex-matched wild-type and homozygous
p110b-RBD-DM mice from intercrosses of heterozygous p110b-RBD-DM an-
imals were used to study bleomycin-induced lung fibrosis. Mice (8–12 weeks
old) were anaesthetized with isoflurane, and bleomycin in sterile normal saline
(1.25 U/kg) or saline alone (50 ml) was given by intratracheal instillation. After
14 days, mice were culled and lungs were recovered for further analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Discussion, Extended Experi-
mental Procedures, seven figures, and one table and can be found with this
article online at http://dx.doi.org/10.1016/j.cell.2013.04.031.
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